JPH07500504A - Langerhans in its pure form - Google Patents
Langerhans in its pure formInfo
- Publication number
- JPH07500504A JPH07500504A JP6505891A JP50589193A JPH07500504A JP H07500504 A JPH07500504 A JP H07500504A JP 6505891 A JP6505891 A JP 6505891A JP 50589193 A JP50589193 A JP 50589193A JP H07500504 A JPH07500504 A JP H07500504A
- Authority
- JP
- Japan
- Prior art keywords
- islets
- langerhans
- cellular material
- islet
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 30
- 238000005119 centrifugation Methods 0.000 claims description 27
- 210000000496 pancreas Anatomy 0.000 claims description 27
- 238000000926 separation method Methods 0.000 claims description 26
- 230000001413 cellular effect Effects 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 24
- 210000004153 islets of langerhan Anatomy 0.000 claims description 23
- 238000004062 sedimentation Methods 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 230000005847 immunogenicity Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 230000003189 isokinetic effect Effects 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000004382 Amylase Substances 0.000 claims description 5
- 102000013142 Amylases Human genes 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 5
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 235000019418 amylase Nutrition 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 230000003914 insulin secretion Effects 0.000 claims description 5
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 5
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 238000011109 contamination Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 210000000955 splenic vein Anatomy 0.000 claims description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 9
- 230000029087 digestion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000277 pancreatic duct Anatomy 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 238000011403 purification operation Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001738 isopycnic centrifugation Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 101100128278 Mus musculus Lins1 gene Proteins 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001006154 Phara Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003084 xenolytic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pens And Brushes (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 純粋な形態におけるランゲルハンス島 本発明の目的は、精製された細胞粒子の量に比べて98%以上の高純度レベルを 有する単離ランゲルハンス島の調製物およびそのような調製物の製法、並びにヒ トもしくは動物体に対するその調製物の診断的および/または治療的用途にある 。[Detailed description of the invention] Langerhans in its pure form The objective of the present invention is to achieve a high purity level of 98% or more compared to the amount of purified cell particles. Preparations of isolated islets of Langerhans having and methods of making such preparations, and diagnostic and/or therapeutic use of its preparations on animals or animals; .
1922年、BantingおよびBe5tによる糖尿病治療に対するインシュ リンの導入以来、致死的結果をもたらす糖尿病のケト酸性昏睡は、全く稀になっ た。しかしながら、インシュリンによる治療は、広範囲の糖尿病症例に見られる ような、例えば眼、腎臓および神経組織に対する細管1966年時点では、健康 な膵臓の移植によって、一般に知られているインシュリン治療の限界を緩和する 努力がなされて来た。しかしながら、外科的操作の危険、特に受容者のその部分 における体の拒絶反応を防ぐための長期間の免疫抑制処置をすることは、著名な 糖尿病学者の意見においては、選択枝としての膵臓移植を正当なものとはしてな い。In 1922, Banting and Be5t developed an insulin for the treatment of diabetes. Since the introduction of phosphorus, diabetic keto-acid coma, with its fatal consequences, has become completely rare. Ta. However, treatment with insulin is seen in a wide range of diabetic cases. As of 1966, the health Alleviating the limitations of commonly known insulin therapy through pancreatic transplantation Efforts have been made. However, the risks of surgical manipulation, especially that part of the recipient Providing long-term immunosuppressive treatment to prevent the body's rejection of In the opinion of diabetologists, pancreas transplantation as an option should not be justified. stomach.
そこで、脳死の臓器提供者(事故の犠牲者のような)の膵臓から得たそのままの 臓器を移植することよりむしろ別の努力、インシュリンを産生ずるランゲルハン ス島ヲ轡離し、それのみを移植する努力、静脈間(肝門静脈)にそれを導入する ことが、最も顕著な応用であるが、そのような努力が長い間なされて来た。動物 における数多くの試験によって、門脈内に移植された島が、門静脈の末端分枝に 侵入し、血糖レベルのような要求に依存したインシュリン産生を吸収し、糖尿病 性代謝を調整し、そして生命を脅かす糖尿病の合併症を防ぐことが知られている 。さらに、数多くの動物に施された試験によって、低レベルの免疫性島移植の使 用とともに、膵臓移植とは反対に、島移植は、糖尿病の受容者の免疫抑制処置を 必要としないか、あるいは一時的にのみ必要とすることが知られる。Therefore, an intact organ obtained from the pancreas of a brain-dead organ donor (such as an accident victim) Langerhan's other effort, rather than transplanting organs, is to produce insulin. Efforts to separate the islet and transplant only it, introducing it between the veins (hepatic portal vein) Although this is the most prominent application, such efforts have been made for a long time. animal Numerous studies have shown that islets implanted within the portal vein have a invades and absorbs insulin production, which depends on demands like blood sugar levels, leading to diabetes Known to regulate sexual metabolism and prevent life-threatening diabetes complications . Furthermore, studies conducted on numerous animals have shown that low levels of immune In contrast to pancreas transplantation, islet transplantation can be used with immunosuppressive treatment in diabetic recipients. It is known that it is not needed or is only needed temporarily.
同様に、糖尿病のヒトにおける島移植の証拠がある。唯−人ではあるが女性患者 が、島移植後、はとんど2年間インシュリン使用なしで生存した(Warnoc k G、L、 et al、、 Diabetologia 35: 89−9 5.1992) oさらに多くの試行における成功の欠如は、不十分な純度レベ ル、すなわち外分泌断片、管要素、リンパ節および血管のような島以外の組織の 分離が不十分な島懸濁液の移植によって説明される。そのような不十分な純度レ ベルの島懸濁液は、非常に高い免疫原性が特徴であり、そして移植後、体の拒絶 反応の高頻度の出現によって危険にさらされる。Similarly, there is evidence of islet transplantation in diabetic humans. The only female patient However, after islet transplantation, most patients survived without insulin use for only 2 years (Warnoc et al. k G, L, et al, Diabetologia 35: 89-9 5.1992) o Lack of success in more trials may be due to insufficient purity level. of non-island tissues such as exocrine fragments, ductal elements, lymph nodes and blood vessels. Illustrated by transplantation of poorly separated islet suspensions. Such insufficient purity level Bell's islet suspension is characterized by very high immunogenicity, and after transplantation, the body rejects it. Endangered by the frequent occurrence of reactions.
心臓、肝臓および腎臓移植において有効であると証明された免疫抑制治療プロト コールの使用にも拘らず、不純な島懸濁液は、初期段階において拒絶される。専 門家の関心の焦点は、提供者の臓器から得られた特に純粋な形態における、それ ぞれ、移植島懸濁液の精製操作、またはそれらの調製物であった。Immunosuppressive treatment protocols proven effective in heart, liver and kidney transplants Despite the use of coal, impure islet suspensions are rejected at an early stage. Dedicated The focus of the Monke's interest is on the use of donor organs, especially in their purest form. Each was a purification operation of a transplanted islet suspension or a preparation thereof.
公開されたPC=T出願第1088109667号において、細胞懸濁液、例え ば結合している組織4・ら分離されたランゲルノ1ンス島を含有する懸濁液を、 いわゆる密度勾配遠心分離にかけることによって、膵臓のような提供臓器由来の 精製細胞懸濁液を得る目的をもった方法が記載されている。多数の出版物、特に 、London N、 J、 M、 et al、 : l5let puri ficationのような総論において。Pancratic l5let C e1l Transplantation(Ricordi C,。In published PC=T application no. 1088109667, cell suspensions, e.g. For example, a suspension containing Langernon's islets separated from the connective tissue 4, By subjecting it to so-called density gradient centrifugation, it is possible to A method is described with the aim of obtaining a purified cell suspension. Numerous publications, especially , London N, J, M, et al, : l5let puri In a general discussion such as fication. Pancratic l5let C e1l Transplantation (Ricordi C,.
Editor)、 R,G、 Landes、^ustin、 Texas、 IIs^、 pp 113−123.1992:においては、種々の密度の細胞 および/または細胞凝集体の可変沈降(または等密度遠心とも言われる)に主と して基づく密度勾配遠心という特殊な方法、およびランゲルハンス島の細胞凝集 体をもつ懸濁液に対する精製方法としてのその応用が記載されており、その方法 によって、精製細胞粒子の量に比べて90%以上の純度レベルのものが得られた 。それゆえ外分泌断片、管要素、リンパ節および血管のような望ましくない細胞 粒子による有用な島懸濁液の汚染は、100%拡大での光学顕微鏡下で、容易に 見分けることができる。Editor), R, G, Landes, ^ustin, Texas, In IIs^, pp 113-123.1992: cells of various densities and/or mainly for variable sedimentation (also called isopycnal centrifugation) of cell aggregates. A special method called density gradient centrifugation based on Its application as a purification method for suspensions with bodies is described and the method A purity level of over 90% was obtained compared to the amount of purified cell particles. . Therefore unwanted cells such as exocrine fragments, ductal elements, lymph nodes and blood vessels Contamination of useful islet suspensions by particles is easily observed under a light microscope at 100% magnification. can be distinguished.
本発明は、特に高純度レベルの単離ランゲルハンス島の調製物を作製すること、 および標準試験の使用によって明白な試験管内での免疫原性を低下させることを 目的とする。The present invention provides a method for producing preparations of isolated islets of Langerhans with particularly high levels of purity; and to reduce apparent in vitro immunogenicity through the use of standard tests. purpose.
その問題は、精製された細胞材料の量に比べて98%を超える純度レベルの単離 ランゲルハンス島調製物、およびそのような調製物を作製する方法を包含する本 発明によって解決される。The problem lies in the isolation of purity levels greater than 98% compared to the amount of purified cellular material. Book containing islet of Langerhans preparations and methods of making such preparations Solved by invention.
本発明による単離ランゲル/N7ス島調製物は、次のことを特徴とする: 種々の密度の細胞材料の可変沈降に主として基づくただ一回の分離手段を使用し た後に、島懸濁液に比較してランゲルノ1ンス島の純度レベルが増大する。The isolated Langer/N7 islet preparation according to the invention is characterized by: Uses a single separation means based primarily on variable sedimentation of cellular material of varying densities After purification, the purity level of Langernon's islets compared to islet suspensions is increased.
本発明による単離ランゲルハンス島本発明は、さらに、付加的暑こ次のことを特 徴とする・ 高容量の損失が3%以下であり;大部分の精製細胞材料の直径が100μmを超 え;免疫原性の低下が平均75%を超え:潜在的な微生物汚染が減少する;ミク ロ蛍光法による生存率指標が変わらない;試験管内でのグルコース刺激によるイ ンシュリン分泌指標の増加が平均50%を超え;そして数種の免疫調節処理の一 つを行った後の高容量の回収率が増大する。The isolated islets of Langerhans according to the present invention further features the following: As a sign High capacity loss is less than 3%; most purified cell material has a diameter greater than 100 μm E; Reduction in immunogenicity exceeds 75% on average: Potential microbial contamination is reduced; Miku (b) Fluorescence-based viability indicators remain unchanged; in vitro glucose stimulation Increases in insulin secretion indicators average more than 50%; and one of several immunomodulatory treatments Increased recovery of high volumes after one step.
これらの特徴は、種々の直径の細胞材料の可変沈降に主として基づく1つの分離 手段を適用後、まだ種々の直径の細胞材料の可変沈降に主として基づく次の分離 手段を適用する前に、予備精製された島懸濁液に比較して得られ、この特徴は、 詳細には、発明者の方法の特徴としてこの後に記載される。These features make one separation based primarily on variable sedimentation of cellular material of different diameters. After applying the method, the following separation is still mainly based on variable sedimentation of cellular material of various diameters. This feature is obtained in comparison to pre-purified islet suspensions before applying the means. In detail, features of the inventor's method are described hereinafter.
その他の特徴は、膨張した膵臓の組織結合を除去した後の、続いて実施される分 離法の使用前の島懸濁液に比較して、アミラーゼ含量が0゜05%未満であって もよい。その調製物は、また生理学的に受容可蛯な担体液も含有する。Other characteristics are the The amylase content is less than 0.05% compared to the islet suspension before use of the separation method. Good too. The preparation also contains a physiologically acceptable carrier fluid.
本発明による単離ランゲルハンス島調製物の純度は、光学顕微鏡下で明瞭に確認 できる。The purity of the isolated islet of Langerhans preparation according to the invention is clearly confirmed under a light microscope. can.
上記の、そして以下の記述における一般的定義および用語は、発明の説明の枠組 みにおいて、次の意味を有する:用語“細胞材料(cell material )”とは、細胞の断片もしくは粒子、完全ト細胞、および細胞クラスグーとも言 われる完全な細胞の集塊ないし細物集塊を包含する。The general definitions and terms in the description above and below are used within the framework of the description of the invention. In this context, the term “cell material” has the following meanings: )” also refers to cell fragments or particles, whole cells, and cell clusters. It includes complete cell clumps or fine clumps.
単離ランゲルハンス島調製物は、次のような方法に従って、ヒトおよび動物膵臓 の提供臓器より得られ、診断および/または治療処置のために、好ましくはヒト に対して、しかし同様に動物にも使用することができる。タイプ1およびIIの 両糖尿病の処置に関する治療法のためには、ヒト膵臓由来の単離ランゲルハンス 島調製物が好適である。利用し得る提供者からのヒト膵臓に限度があり、糖尿病 患者の割合が高いために、同様にして動物の膵臓が用いられる。そのような場合 には、ブタ膵臓が好ましい。診断用には、動物、特にブタ由来の単離ランゲルハ ンス島調製物が、好適である。診断用のためのヒト膵臓由来の単離ランゲルハン ス島調製物は、本発明のその他の主題である。Isolated islets of Langerhans preparations are prepared from human and animal pancreas according to the following methods: preferably from a human donor organ for diagnostic and/or therapeutic treatment. However, it can be used on animals as well. Type 1 and II For therapeutics regarding the treatment of both diabetes, isolated Langerhans derived from human pancreas Islet preparations are preferred. There is limited human pancreas from available donors, and diabetes Due to the high proportion of patients, animal pancreas is also used. in such case porcine pancreas is preferred. For diagnostic purposes, isolated Langerha islet preparations are preferred. Isolated Langerhan from human pancreas for diagnostic use Isla preparations are another subject of the invention.
その調製物は、生理学的に受容可能な導入液中の単離ランゲルハンス島懸濁液の 形で、適切に用いられ、その液は、静脈口(肝臓の門静脈)か、そのほか牌静脈 、牌髄内、胃液膜下、大綱嚢内、大網被弁内に、腹腔内、筋肉内、皮下、脳内、 もしくは皐丸内注射によって、注入される。The preparation consists of a suspension of isolated islets of Langerhans in a physiologically acceptable introduction fluid. When used appropriately, the fluid is administered either to the ostium of the liver (portal vein of the liver) or to the splenic vein. , intramedullary, subgastric, intraperitoneal, intramuscular, subcutaneous, cerebral, intraperitoneal, intramuscular, subcutaneous, intracerebral, intraperitoneal, intramuscular, subcutaneous, intracerebral, Alternatively, it can be injected by intracanal injection.
用語“生理学的に受容可能な担体液(carrier f Iuid)”は、ラ ンゲルハンス島の洗浄、診断および移植操作に対して好適であるとそれぞれ文献 に記載されているような全ての水性媒体を意味する。好適な媒体は、通常、Ha nk’ s平衡生理食塩水溶液(ハンクス液)、最小必須培養液、Medium 199、RPM11640、CMRLI066、ライスコンシン大学液等である 。 本発明の主題は、また、細胞材料の98%以上の高い純度レベルをもつ上記 単離ランゲルハンス島懸濁液の作製方法である。この方法は、次のような操作上 の態様によって特徴付けられ仇すなわち a)膵臓は、ゴ1ラゲナーゼおよび/またはその他のプロテアーゼを含有する可 能性のある生理学的に受容可能な導入液の使用によって膨張させられ、そしてそ の他の細胞材料とともにランゲルハンス島が、消化を通して組織結合から抽出さ れる; b)抽出されたランゲルハンス島が、種々の直径の細胞凝集体の可変沈降に主と して基づく少なくとも一つの分離手段を用いて付加細胞材料から分離される、そ して必要ならば C)分離されたランゲルハンス島が、それらの潜在的な免疫原性/抗原性を減少 させる処理を施され、そして/またはそのそれぞれの島が保存される。The term "physiologically acceptable carrier fluid" The literature suggests that it is suitable for cleaning, diagnosis and transplantation procedures of islets of Ngerhans, respectively. means all aqueous media as described in . A suitable medium is typically Ha nk's balanced physiological saline solution (Hank's solution), minimum essential culture medium, Medium 199, RPM11640, CMRLI066, Rice Consin University liquid, etc. . The subject of the present invention also provides the above-mentioned cell material with a high purity level of more than 98%. This is a method for preparing an isolated islet of Langerhans suspension. This method is useful for operations such as: Characterized by aspects of the enemy, i.e. a) The pancreas may contain Golagenase and/or other proteases. by the use of a physiologically acceptable introduction fluid capable of The islets of Langerhans along with other cellular material are extracted from tissue connections through digestion. be; b) The extracted islets of Langerhans are mainly composed of variable sedimentation of cell aggregates of different diameters. separated from the additional cellular material using at least one separation means based on and if necessary C) Isolated islets of Langerhans reduce their potential immunogenicity/antigenicity and/or their respective islands are preserved.
操作一段階a) 操作におけるこの段階は、通常既知であり、一般には、ランゲルハンス島の普通 の単離および精製法において適用される。Operation step a) This stage of operation is usually known and generally isolation and purification methods.
用語“膨張(distention)”は、膨張(expansi。The term "distention" refers to expansion.
n)を指す。膨張の目的のために、膵臓、すなわちヒトもしくはブタの膵臓の出 口管路、それを通して膵臓の外分泌部において産生された消化酵素が小腸中に放 出されるその管路に、カニユーレが挿入される;このカニユーレを通じて、通常 、膵臓組織1グラム当たり、約0. 1〜1゜0%(W/V)コラゲナーゼを有 するハンクス液2mlが、膵臓管路中に逆行して注入される。n). For the purpose of dilation, the pancreas, i.e. the output of the human or porcine pancreas, is oral tract, through which digestive enzymes produced in the exocrine part of the pancreas are released into the small intestine. A cannula is inserted into the conduit that exits; through this cannula, the , per gram of pancreatic tissue, approximately 0. Contains 1-1°0% (W/V) collagenase 2 ml of Hank's solution is retrogradely injected into the pancreatic duct.
この操作段階は、好ましくは、”Lacy P、E、 et al、、 Dia betes 16: 35−39 (1967)およびGray D、W、R, et al、、 Diabetes 33: 1055−1061 (1984 )”に記載の方法に従って実施される。This operational step is preferably carried out by “Lacy P, E, et al., Dia betes 16: 35-39 (1967) and Gray D, W, R, et al, Diabetes 33: 1055-1061 (1984 )”.
用語“、消化”1、消化操作を指す。消化過程において、その膵臓は、酵素的お よび機械的作用の下で、ランゲルハンス島および細胞材料とに分解される。この 方法は、好ましくは、” Ricordi C,et al、 : Diabe tes 37: 413−420.1988 ”ならびにPCT出願公開第WO 88109667号パンフレット記載の方法によって実施される。The term "digestion" 1 refers to the digestion operation. During the digestive process, the pancreas produces enzymatic and and under mechanical action, it is broken down into islets of Langerhans and cellular material. this The method is preferably carried out by “Ricordi C, et al.: Diabe tes 37: 413-420.1988” and PCT Application Publication No. WO It is carried out by the method described in pamphlet No. 88109667.
用語“プロテアーゼ”は、中性プロテアーゼ、クロストリパイン、トリプシン、 エラスターゼ、ジスバーゼ(dispase)等の名で知られている酵素と、さ らに既知の純粋タイプのコラゲナーゼを指す。The term "protease" refers to neutral proteases, clostripain, trypsin, Enzymes known as elastase, dispase, etc. Refers to the known pure type of collagenase.
操作段階a)の終結後、先に示した媒体中の分離されたランゲルハンス島懸濁液 を得ることができるが、それはまだ、付加細胞材料を含有しているので純粋では ない。After the conclusion of operating step a), the isolated islets of Langerhans suspension in the medium indicated above can be obtained, but it is still not pure as it contains additional cellular material. do not have.
操作一段階b) 用語“種々の直径の細胞材料の可変沈降に主として基づ(分離手段(measu re of 5eparation)”とは、一般的に既知の分離操作を指し、 ランゲルハンス島の単離および精製のためのその応用は、いまだ新規であり、そ れ故、本発明の主題を表している。この分離手段は、用語“速度沈降(velo city sedimentation)”のちとに、国際公開において扱われ ており、それは次の操作変法、1グラムにおける沈降、向流遠心(傾斜法)、再 配向された帯状ローターにおける遠心および等速勾配遠心を包含する。ここで好 ましいのは、通常、“等速勾配遠心”と言われている既知の操作変法である。Operation step b) The term “separation means (measu "re of 5 separation)" refers to a generally known separation operation, Its application for isolation and purification of islets of Langerhans is still novel and its Therefore, it represents the subject matter of the present invention. This separation means is defined by the term "velocity sedimentation" (velo). city sedimentation)”, which was treated in international publication. It is based on the following operating variations: sedimentation at 1 gram, countercurrent centrifugation (tilt method), and re- Includes centrifugation in oriented band rotors and isokinetic gradient centrifugation. I like it here Preferred is the known operating variant commonly referred to as "isokinetic gradient centrifugation."
この操作の一つの特に好適な応用形態においては、その等速勾配遠心は、種々の 密度の細胞凝集体の可変沈降に主として基づくその他の分離手段と組み合biら れる。In one particularly preferred application of this operation, the isokinetic gradient centrifugation In combination with other separation means primarily based on sedimentation of variable density cell aggregates, bi et al. It will be done.
用語“種々のt度の細胞凝集体の沈降に主として基づく分離手段”は、通常周知 のその他の分離方法を意味し、それは、またランゲルハンス島の分離および精製 のために応用されて来た(London N、 J」、 、前出、 Page5 、参照)。この分離手段は、用語“等密度遠心法(isopyknicgrad ient centrifugation)”のちとに、国際公開において記載 されている。好適な応用法の記載は、実施例において与えられる。特に好適な操 作の応用形態は、次のことを特徴とする:b)抽出ランゲルハンス島は、種々の 密度および種々の直径の細胞凝集体の可変沈降に主として基づく続いて行われる 分離手段を通じて、付加細胞材料から分離される。The term "separation means based primarily on sedimentation of cell aggregates of various degrees" is generally well known. It also refers to other separation methods of Langerhans isolation and purification. It has been applied for (London N, J”, supra, Page 5 ,reference). This separation means is referred to under the term “isopyknic centrifugation”. described in the international publication after ``ent centrifugation)'' has been done. A description of preferred applications is given in the Examples. Particularly suitable operation The applied form of the production is characterized by the following: b) Extraction of Langerhans is carried out by various A subsequent procedure based primarily on variable sedimentation of cell aggregates of varying density and diameter It is separated from the additional cellular material through the separation means.
操作のその他の応用形態においては、種々の直径および種々の密度の細胞凝集体 の可変沈降に主として基づく分離手段の組み合わせにおいて、逆の順に実施して もよい。In other applications of manipulation, cell aggregates of different diameters and different densities In a combination of separation means based primarily on variable sedimentation of Good too.
等速勾配遠心は、好ましくは: “Pretlow T、 G、 、^nal Biochea+ 41+248−255.1971およびPretlow T 、 G、 II and Pretlov T、 P、、 Ce1l 5epa ration: Methods and 5elected Applica tion、 Vol、 5.^cadei+ic Pr■ ss、 pp 281−309.191117”の生理学的に受容可能な直線的 密度勾配を有する水性媒体中での方法についての記載に従って実施される。出版 物において、そのような媒体は、用語“勾配(gradient)−を与えられ 、いわゆる“グラジェントミキサー”において、または遠心自体の過程において 形成される。その勾配は、遠心管の底部において最も高い密度レベルを有し、そ れより上部に行くほど密度が減少する。勾配形成のための好適な媒体は、例えば 、Ficoll(商標)、Percoll (商標) (phara+acia 、 Freiburg)の名で知られており、ポリシュークロース、ポリビニノ q、°←°ロリドン、アルブミンもしくはデキストランのような補助物質を含有 してもよい。種々の直径の細胞材料の可変沈降に主として基づく分離手段に関し て、勾配を通して沈降した細胞材料の移動は、その最大密度のものが、最小密度 の沈降物質の移動より低いことを特徴とする。遠心過程において、沈降細胞材料 は、非常に一貫した速度で、勾配中を移動する。分離手段は、最初の細胞粒子が 遠心管の底部に達した時に終了する。この方法は、本質的に;密度に関してはそ れほどではないが、直径の異なる細胞材料の分離手段のために好適である。The isokinetic gradient centrifugation is preferably carried out by: “Pretlow T, G, ^nal Biochea+ 41+248-255.1971 and Pretlow T , G, II and Pretlov T, P,, Ce1l 5epa ration: Methods and 5elected Applica tion, Vol. 5. ^cadei+ic Pr■ 281-309.191117” physiologically acceptable linear It is carried out as described for the method in an aqueous medium with a density gradient. publication In the article, such a medium is given the term “gradient”. , in a so-called “gradient mixer” or during the process of centrifugation itself. It is formed. The gradient has the highest density level at the bottom of the centrifuge tube; The density decreases as you go above the surface. Suitable media for gradient formation are e.g. , Ficoll (trademark), Percoll (trademark) (phara+acia , Freiburg), polysucrose, polyvinino q, °←° Contains auxiliary substances such as lolidone, albumin or dextran You may. Concerning separation means based primarily on variable sedimentation of cellular material of different diameters As a result, the movement of cellular material sedimented through the gradient is such that its highest density reaches its lowest density. It is characterized by a lower movement of sedimentary substances. During the centrifugation process, sedimented cell material moves through the gradient at a very consistent speed. The separation means is such that the initial cell particles Centrifuge ends when the bottom of the tube is reached. This method essentially To a lesser extent, it is suitable for means of separating cellular material of different diameters.
操作一段階C) 潜在的な免疫原性および/または抗原性を減少させる処理、例えば培養、UV照 射、ガンマ線、抗体とのインキュベーションもしくはカプセル化は、前述の応用 形態のための培養物における普通の細胞材料の調製方法に関係しており、それは また、この出願において述べられた文献類に記載されている。凍結保存は、保存 手段として適切な次の段階である。Operation step C) Treatments that reduce potential immunogenicity and/or antigenicity, e.g. culturing, UV irradiation. radiation, gamma rays, incubation with antibodies, or encapsulation may be used for the aforementioned applications. It concerns the preparation method of ordinary cell material in culture for morphology, which It is also described in the documents mentioned in this application. Cryopreservation is preservation This is an appropriate next step.
得られた特別な純度の島によって、その一つの要素が治療上および/または診断 上の知見に対する改善を表している分離手段に続いて、全ての方法を適用した後 に、より良好な結果が達せられる。The special purity of the islets obtained makes it possible for one element to have therapeutic and/or diagnostic potential. After applying all methods following separation measures representing an improvement over the above findings. better results can be achieved.
次の実施例は、本発明を例示しているが、発明を限定するものではない(温度は 摂氏で示される):製造者もしくは出版物の編集者および出版者の所在に関する データは、ドイツ連邦共和国における所在に限定される。The following examples illustrate, but do not limit, the invention (temperatures (in degrees Celsius): regarding the location of the manufacturer or editor and publisher of the publication. Data is limited to locations in the Federal Republic of Germany.
実施例: 1、 膵臓組織 膵臓は、種雌ブタ(ドイツ連邦ハイブリッド飼育計画)から、層殺し、放血し、 そして周囲の脂φ組織から膜に包まれた臓器を注意深く保ちながら腸管を取り除 いた後、摘出されるが、その間無菌の予防措置が取られる。10分間の温暖虚血 が、屠殺過程に含まれる。このようにして得られた臓器は、4℃/39°Fの冷 却Euroco l I ins (商標)溶液(Fresenius、 Ba d Homburg)で、島実験室に移送される。島分離を開始する前の冷却虚 血の時間は、30分である。Example: 1. Pancreatic tissue The pancreas was obtained from sows (German Federal Hybrid Breeding Program) by layer killing and exsanguination. Then, remove the intestinal tract while carefully keeping the membrane-encased organs from the surrounding adipose tissue. It is then removed, during which sterile precautions are taken. Warm ischemia for 10 minutes is included in the slaughter process. The organs thus obtained are cooled at 4°C/39°F. Euroco lins (trademark) solution (Fresenius, Ba d Homburg) and transferred to the island laboratory. Cooling depletion before starting island separation Blood time is 30 minutes.
2、 膵臓の調製および膨張 高調製のその他の全段階は、無菌状態で実施される。膵臓に最も近い膵臓の切片 のみが、島単離のために使用される。調製された臓器片の重量は120gである 。膵臓の出口(膵管)は、右大腿と膵臓近接部の間の切断部でめ、19Gカニユ ーレを使用してカニユーレ挿入し、外科系により結び付けられる。2. Preparation and expansion of pancreas All other steps of high preparation are carried out under aseptic conditions. Section of the pancreas closest to the pancreas used for islet isolation. The weight of prepared organ pieces is 120 g . The outlet of the pancreas (pancreatic duct) is located at the cut between the right thigh and the proximal part of the pancreas. The cannula is inserted using a needle and tied by the surgical system.
膵臓近接部から使用された膵臓切片の重量により、膨張液の容量が決定される。The weight of the pancreatic section used from the proximal pancreas determines the volume of inflation fluid.
膵臓ダラム当たり膨張液2ml、すなわち全240m1が、水平に置かれたカニ ユーレを通して膵管中に逆行して注入される。膨張のためには、0,4%コラゲ ナーゼ(Serva、 Heidelberg、 catalogue no、 17449)含有のライスコンシン大液(UW−溶液) (DuPont、 Bad n。2 ml of distension fluid per pancreatic dam, i.e. a total of 240 ml, was added to the horizontally placed crab. It is injected retrogradely into the pancreatic duct through the urea. For expansion, use 0.4% collagen Serva, Heidelberg, catalog no. 17449) containing rice consin large solution (UW-solution) (DuPont, Bad n.
mburg)が、温度22℃(72°F)で使用される。mburg) is used at a temperature of 22°C (72°F).
膨張が終了した後、さらに周囲の脂肪組織および結合組織、膜に覆われた臓器、 および膨張してない実質が除去される(カニユーレを除いて全15g1すなわち 使用された膵臓の重量は105gである)。After the expansion is complete, the surrounding adipose tissue and connective tissue, organs covered by membranes, and non-distended parenchyma is removed (total 15 g excluding cannula i.e. The weight of the pancreas used is 105 g).
3、 膵臓の消化 ランゲルハンス島(島)が、外分泌断片、管路要素、血管断片、リンパ節等とと もに結合%組織からヒト・ランゲルハンス島の単離のための” Ricordi C,et *r、 :Diabetes 37:413−420.1988− ならびにpcT出願公開第?088109667号パンフレットに記載された 方法により単離される。3. Digestion of the pancreas The islets of Langerhans are divided into exocrine fragments, ductal elements, blood vessel fragments, lymph nodes, etc. Ricordi for the isolation of human islets of Langerhans from connective tissue. C, et *r, : Diabetes 37:413-420.1988- and pcT application publication number? Described in pamphlet No. 088109667 isolated by the method.
この目的のために1、膨張膵臓片が、その構造はPCT出願公開第WO3810 9667号パンフレットに記載されている450m1容の消化容器の底に、7個 のガラス球(マーブル)とともに置かれる。次いで、容器の下方部分、400μ サイズの篩、容器の蓋、およびコラーゲン溶液の再循環のための配管系が、PC T出願公開第WO88109667号パンフレットの図2に記載されているよう に組み立てられる。For this purpose 1, an inflated pancreatic piece, the structure of which is described in PCT Application Publication No. WO 3810 7 pieces at the bottom of the 450m1 capacity digestion vessel described in pamphlet No. 9667. It is placed with a glass ball (marble). Then the lower part of the container, 400μ The size sieve, container lid, and piping system for collagen solution recirculation are As described in Figure 2 of the pamphlet of T application publication number WO88109667 be assembled.
配管系は、付加的にハンクス液で満たされ、ポンプは、その溶液を再循環するた めに始動され、そして流速は、200m1/分にセットされる。膨張膵臓とガラ ス球(マーブル)の入った消化容器は、垂直軸方向に、振動速度300回/分、 振幅10mmにおいて動かされる。消化容器中の温度は、熱交換器の使用により 1分間に3℃で、32−34℃(90−94°F)に上昇する。再循環期(期1 )の間、温度はこのレベルで一定に維持される。The piping system is additionally filled with Hank's solution and a pump is used to recirculate that solution. and the flow rate is set to 200 ml/min. swollen pancreas and gala The digestion vessel containing the marbles was vibrated at a vibration rate of 300 times/min in the vertical axis direction. It is moved at an amplitude of 10 mm. The temperature inside the digester is controlled by the use of a heat exchanger. Rise to 32-34°C (90-94°F) at 3°C per minute. Recirculation phase (phase 1 ), the temperature is kept constant at this level.
1−2分間隔で配管系から採取されたサンプルの顕微鏡観察を用いて、膵臓消化 の過程が注意深く続けられる。14分後、サンプル中には、多数の遊離された島 がまず確認される。コラゲナーゼを含有するハンクス液の再循環は、この時点で 停止されて、その容器に、酵素を含まない新しいハンクス液が、サンプル(期I I)中に、もはや島が見られなくなるまで15分間流速250m1/分で流され る。期IIの間の温度は、15分間に32−34℃から15℃まで低下する。遊 離された島を、コラゲナーゼおよび彬臓によって放出されるその他のタンパク分 解酵素から保護するために、その組織懸濁液は、冷却された(8°C)コーン型 底部をもつハンクス液35m1の入った250m1容遠心カツプに入れられる。Pancreatic digestion using microscopic observation of samples taken from the plumbing system at 1-2 minute intervals. The process continues carefully. After 14 minutes, there were many liberated islands in the sample. is checked first. Recirculation of Hank's solution containing collagenase is recommended at this point. The sample (phase I) is stopped and fresh Hank's solution without enzyme is added to the container. I) flowed at a flow rate of 250 m/min for 15 minutes until no islands were visible anymore. Ru. During phase II, the temperature drops from 32-34°C to 15°C in 15 minutes. play The detached islets are treated with collagenase and other proteins released by the liver. To protect from enzymatic degradation, the tissue suspension was placed in a chilled (8°C) cone mold. The bottom is placed in a 250 ml centrifuge cup containing 35 ml of Hank's solution.
組織懸濁液で満たされたこれらの遠心カップは、4℃(39°F)、120xg での遠心に2分間懸けられ、残液が捨てられ、完全なペレットがUW−溶液(4 ℃)で200m1に満たされ、次いで再懸濁されて、8℃(48’ F)におい て保存される。These centrifuge cups filled with tissue suspension were heated at 4°C (39°F) and 120xg. Centrifuge for 2 minutes at 200 ml at 8°C (48'F), then resuspended and stored at 8°C (48'F). will be saved.
代表的サンプルが、島の数、島の容量、DNA含量、インシュリン濃度およびア ミラーゼ活性の測定のために採取される。Representative samples were analyzed for islet number, islet volume, DNA content, insulin concentration and insulin concentration. Collected for measurement of mylase activity.
4、 等密度勾配遠心 そのほかに、遠心(2分間、4℃、120xg)の後、残液が捨てられ、その濃 縮物(ペレット)が、熱不活化された新生子ウシ血清(NC3゜Biochro m、 Berlin) 15m I中に、容量32m1に再懸濁され、そして6 00m1容ガラスカツプに移されて、フィコール−ナトリウム−ジアドリゾエー ト(Ficol 1−sodium−diatrl−5odiu溶液400m1 で満たされる。この溶液は、Seromed(商標)−ficoll 5epa r a t o r (1,090g/cc、 Biochros、 Berl in)500m l、IM HEPE S 12 m l (Gibco、 E ggenstein)、ペニシリン−ストレプトマイシン(lO,0OOIU/ ml P、、 10. OOjg/ml S、、 Flow、 Irvine、 GB)5m l 、 I NN a OH1m1およびMe d i um 199(lx、 Biochros、 Berlin)50m lを混合するこ とによって作製される。ガラスカップの内容物(底部層)は、500m1の血液 輸送バッグ(Biopack Model、 Biotrans、 Dreie ich)に移されて、それが血液細胞精製装置2991 (Cobe、 Kir chheim/Munich)(Blood cell Process4 P rocessing Set、 Cobe、 Catalogue No、 9 12−647−819)中に予め設置されたディスポーザブルシステムに、規定 に従って結合される。次いで、血液輸送バッグの内容物は、そのディスポーザブ ルシステム中に移される。血液細胞プロセッサー遠心機は、2分間に200OR PMに加速される。Medium199の200m1が、遠心を240ORPM に加速しながら、その底部層の上へ、ホースポンプを用いて流速5Qml/分で 重層される。続いて、ディスポーザブルシステムは、脱気されて、供給ラインは 閉ざされる。室温で240ORPM10分の遠心後、そして統合した“グラジェ ントアンローダ−(gradient unloader)”を用いて同一回転 速度において、次の画分が“ブロモ・ソシング・セット”から遠心カップに、順 次移行される:画分1: 180m1! 画分IIa: 25mj! 画分11b: 10mf 画分IIc: 10mj! 画分IId: 10mj! 両分IIe: 25m1 画分III: 290mjl’ 遠心を止めた後、“プロセッシング・セ・ソト”が、取り出され、そして 画分IV: 50m1 が、ガラスカップに移される。4. Isopycnic gradient centrifugation In addition, after centrifugation (2 minutes, 4°C, 120xg), the remaining liquid is discarded and the concentrated The condensate (pellet) was heated using heat-inactivated newborn calf serum (NC3゜Biochrom). m, Berlin) 15m I, resuspended in a volume of 32 ml and 6 Transferred to a 00ml glass cup and added Ficoll-sodium-diadrizoe. (Ficol 1-sodium-diatrl-5odiu solution 400ml filled with. This solution consists of Seromed™-ficoll 5epa r a o r (1,090g/cc, Biochros, Berl in) 500ml, IM HEPE S 12ml (Gibco, E ggenstein), penicillin-streptomycin (lO,0OOIU/ ml P,, 10. OOjg/ml S, Flow, Irvine, GB) 5 ml, I NN a OH 1 ml and Me d i um 199 (lx, Biochros, Berlin) by mixing 50ml It is produced by The contents of the glass cup (bottom layer) are 500ml of blood Transport bag (Biopack Model, Biotrans, Dreie ich), which is then transferred to Blood Cell Purifier 2991 (Cobe, Kir. chheim/Munich) (Blood cell Process4 P rocessing Set, Cobe, Catalog No. 9 12-647-819) combined according to The contents of the blood transport bag are then placed in its disposable bag. transferred into the file system. Blood Cell Processor Centrifuge 200OR per 2 minutes Accelerated by PM. 200ml of Medium199 centrifuges at 240ORPM onto the bottom layer using a hose pump at a flow rate of 5 Qml/min while accelerating to Layered. Subsequently, the disposable system is degassed and the supply line is Closed. After centrifugation for 10 min at 240 ORPM at room temperature, and same rotation using a gradient unloader. At speed, the following fractions are sequentially transferred from the “Bromo Sossing Set” to the centrifuge cup. Next transferred: Fraction 1: 180ml! Fraction IIa: 25 mj! Fraction 11b: 10mf Fraction IIc: 10 mj! Fraction IId: 10 mj! Both parts IIe: 25m1 Fraction III: 290 mjl' After stopping the centrifugation, the “processing sesoto” is removed and Fraction IV: 50ml is transferred to a glass cup.
各両分力、10%NC3含有Medium199)こ懸濁され、室温で250% gS分間遠心されA0残液力(捨てられ、その画分のベレ、、ト(ま、別々に1 0%ウシ胎児血清(ics、 Biochrow、 Berlin)、1%ペニ シIJンーストレプトマイシン溶液および2mMグルシルルタミン(bioch rom, Berlin)含有のLeibovitz Medium(Bioc hrom, Berlin)に再懸濁され:その懸濁液(嘘、1音養)(イアル に移され、それらの島純度(島組織で覆われた表面の百分率)3こ関して評価さ れる。大量の島の塊を有する両分は、殆ど外分泌の混入はなく、続いて、等速勾 配遠心に懸けられる。Both components were suspended in Medium 199) containing 10% NC3 and 250% It was centrifuged for gS minutes, the A0 residual liquid was discarded, and the fraction was collected separately. 0% fetal bovine serum (ics, Biochrow, Berlin), 1% penile CiJ-streptomycin solution and 2mM glycyl glutamine (bioch rom, Berlin) containing Leibovitz Medium (Bioc hrom, Berlin): The suspension (lie, 1 sound) (Ial and evaluated for their islet purity (percentage of surface covered by islet tissue). It will be done. Both halves, which have a large number of islet clusters, have almost no exocrine contamination, followed by isokinetic gradients. suspended in a centrifuge.
代表的サンプルが、島の数、島の容量、DNA含量、インシュリン濃度、アミラ ーゼ活性、試験管内グルコース依存性インシュリン分泌、並びに免疫原性の測定 のために採取される。Representative samples include islet number, islet volume, DNA content, insulin concentration, and Measurement of enzyme activity, in vitro glucose-dependent insulin secretion, and immunogenicity collected for.
5、 等速勾配遠心 高さ16mm、直径31.5mmの100ml容ポリカーボネート製丸底遠心管 (Nalge, Braunschweig)に、FicollおよびLeib ovitz Medium4mlよりなる底部層(クッション)、高す15mm ,1.026g/ccおよび16℃の粘度3.5cPが、ビペ,。5. Constant velocity gradient centrifugation 100ml polycarbonate round bottom centrifuge tube with a height of 16mm and a diameter of 31.5mm (Nalge, Braunschweig), Ficoll and Leib Bottom layer (cushion) made of ovitz Medium 4ml, height 15mm , 1.026 g/cc and a viscosity of 3.5 cP at 16°C.
トで注入される。Injected at
二基の勾配作成器を用いて、FicollおよびlejbovitzMediu mよりなる、76ml量、高さ120mm,密度率1.026 〜1. 017 g/ c cおよび16℃(60°F)の粘度範囲3.50P〜2.OcPの 連続勾配が、底部層(クッション)の上に添加される。Using two gradient generators, Ficoll and lejbovitz Mediu 76 ml volume, height 120 mm, density rate 1.026 to 1. 017 g/c c and 16°C (60°F) viscosity range 3.50P to 2. OcP's A continuous gradient is added on top of the bottom layer (cushion).
この連続勾配の上に、高さ8mmおよび50.000島当量(1島当量=容量補 正された品数、1島当量は、直径150μmの1島を表す(Ricordi C .et al.Acta Diabetol Lat 27 : 185−19 5. 1990参照)までに相当するサンプル5mlおよび残っているLeib ovitz Medium中の細胞塊錦加えられる。 底部層(り・ソション) 、勾配層およびサンプルを有する遠心管が、遠心機中に置かれるが、その状態1 t、Hettich Rotixa RP遠心機(Hettich, Tutt lingen)(5094型ピポタルローターおよび100ml容遠心管を納め るための適切な付属品およびreduc t tonsを有する)の中心力箋ら の距離が、クッションと勾配間22.2cm,そしてサンプルと勾配間10。On top of this continuous slope, a height of 8 mm and 50.000 island equivalents (1 island equivalent = volume compensation The corrected number of items and one island equivalent represent one island with a diameter of 150 μm (Ricordi C .. etal. Acta Diabetol Lat 27: 185-19 5. 1990) and the remaining Leib Cell mass in Ovitz Medium is added. Bottom layer , a centrifuge tube with a gradient layer and a sample is placed in a centrifuge, whose state 1 Hettich Rotixa RP Centrifuge (Hettich, Tutt lingen) (contains a 5094 type pivotal rotor and a 100ml centrifuge tube) central force (with appropriate accessories and reduce tons) The distance between the cushion and the gradient is 22.2 cm, and the distance between the sample and the gradient is 10 cm.
2cmである。It is 2cm.
遠心管は、30秒間に49QRPMまで加速される。このRPMにおいては、サ ンプルと勾配間の層に、27.4xgの遠心力が作用する。The centrifuge tube is accelerated to 49QRPM in 30 seconds. In this RPM, the support A centrifugal force of 27.4×g acts on the layer between the sample and the gradient.
遠心は、16°で60秒間行われ、30秒以上でかけてORPMまで減速する。Centrifugation is performed at 16° for 60 seconds and decelerated to ORPM over 30 seconds.
遠心管が、遠心機から取り出され;8Qmlよりなる第1画分およびLeibo vitz Mediumで希釈された5mlの第2画分が吸引されて、さらに1 6°で120xg2分間以上遠心される。残液は捨てられ、残っている細胞懸濁 液は、Leibovitz Mediumもしくは他の培養液、および適切な添 加剤を用いて再懸濁される。A centrifuge tube is removed from the centrifuge; a first fraction consisting of 8Qml and Leibo A second fraction of 5 ml diluted with Vitz Medium is aspirated and further 1 Centrifuge at 120xg for 2 minutes at 6°. The residual liquid is discarded and the remaining cell suspension The solution is Leibovitz Medium or other culture medium and appropriate supplements. resuspended using additives.
代表的サンプルが、島の数、島の容量、DNA含量、インシュリン濃度、アミラ ーゼ活性、試験管内グルコース依存性インシュリン分泌、並びに免疫原性の測定 のために採取される。Representative samples include islet number, islet volume, DNA content, insulin concentration, and Measurement of enzyme activity, in vitro glucose-dependent insulin secretion, and immunogenicity collected for.
得られた高野濁液は、以後の応用、例えば培養のために利用することができる。The obtained Takano suspension can be used for subsequent applications, such as culture.
6、 試験 島の数、島の容量、インシュリン濃度、ミクロ蛍光生存試験、試験管内グルコー ス依存性インシュリン分泌が、国際標準法(Ricordi C. et al 、 Acta Diabetol. Lad,前出)により個々のサンプ11に つL)て沖1定される。DNA含量の測定は、“Labarca C. and Paigen K.、^nal Biochem 102: 344−352 . 1980”による方法に従って行われる。個々のサンプルのアミラーゼ活性 (ま、αーアミラーゼEPS (商標)キット(Boehringer. Ma nnheim. Mannheim)を用L1て沖1定される。免疫原性を決定 するために、リンパ球−島混合培養が実施される(Ulrichs K. et al. : Hort Metabol. Res. 25/S: 123− 127. 1990、参照)。ブタの島100個が、ヒトリンパ球105個とと もに37℃(99°F)で3日間培養され、続いて3H−チミジン10μCiを 添加後、島および異種リンパ球が、20時間混合培養される。リンパ球の増殖は 、3H−チミジン取り込みと相関があり、カウンターを通してカウント7分で示 され、対照値と比較して変換後、刺激指数として表される。6. Exam islet number, islet volume, insulin concentration, microfluorescence survival test, in vitro glucose Gas-dependent insulin secretion is determined by the international standard method (Ricordi C. et al. , Acta Diabetol. Lad, supra) to each sump 11. L) and offshore is determined. Measurement of DNA content was performed according to “Labarca C. and Paigen K. , ^nal Biochem 102: 344-352 .. amylase activity of individual samples. (Ma, α-amylase EPS (trademark) kit (Boehringer. nnheim. Mannheim) was used for L1 and Oki 1 was determined. Determine immunogenicity To do this, mixed lymphocyte-islet cultures are performed (Ulrichs K. et al. al. : Hort Metabol. Res. 25/S: 123- 127. 1990, see). 100 pig islets contain 105 human lymphocytes The cells were incubated at 37°C (99°F) for 3 days, followed by 10 μCi of 3H-thymidine. After addition, islets and xenolytic lymphocytes are mixed in culture for 20 hours. proliferation of lymphocytes , is correlated with 3H-thymidine incorporation, and is counted through a counter at 7 minutes. and compared with control values and expressed as stimulation index after transformation.
表1.2種の連続して実施される精製操作(等密度遠心法および等速勾配遠心法 )を用いるブタ膵臓組織由来のランゲルハンス島調製物の結果。Table 1. Two sequential purification operations (isopycnic centrifugation and isokinetic gradient centrifugation) ) Results of preparation of islets of Langerhans from porcine pancreatic tissue.
IPGZ前 IPGZ後 IKGZ前 IKGZI島の数 219.985 1 56.849 152.332 99.016島の容量(μf ) 623 4 58 445 432アミラーゼ(U) 729, 644. 76 402, 773 165, 916 72. 748インシユリン(U) 379.6 236.3 212.6 151.5D N A (m g ) 365. 508 6, 643 2, 321 1. 820生存率(%) 98. 7 98. 5潅流 − PI: 0.48 − PI: 4.44免疫原性 − 28. 5 2. 3 島の容量 100% 73.5% 71.4% 69.3%アミラーゼ 100 % 0. 055% 0. 023% 0.010%インシュリン 100% 62.2% 56.9% 39.9%D N A 100% 182% 0.6 3% 0. 5096表2.2種の連続して実施される精製操作(等密度遠心法 および等速勾配遠心法)を用いるブタ膵臓組織由来のランゲルハンス島調製物の 結果。Before IPGZ After IPGZ Before IKGZ Number of IKGZI islands 219.985 1 56.849 152.332 99.016 Island capacity (μf) 623 4 58 445 432 Amylase (U) 729, 644. 76 402, 773 165, 916 72. 748 Insulin (U) 379.6 236.3 212.6 151.5D N A (mg) 365. 508 6, 643 2, 321 1. 820 Survival rate (%) 98. 7 98. 5 Perfusion - PI: 0.48 - PI: 4.44 Immunogenicity - 28. 5 2. 3 Island capacity 100% 73.5% 71.4% 69.3% Amylase 100 % 0. 055% 0. 023% 0.010% insulin 100% 62.2% 56.9% 39.9% D N A 100% 182% 0.6 3% 0. 5096 Table 2. Two consecutive purification operations (isopycnic centrifugation islets of Langerhans preparations from porcine pancreatic tissue using isokinetic gradient centrifugation). result.
平均値 +SEM IPGZ後 IKGZ後島の容量(μm) 321±44. 2 315.5±39.4生存率(%) 99.2± 0.3 99.1+ 0 .4免疫原性 100%*24劃%±6.4%*(IPGZ後の刺激指数=10 0%) I PGZ : 等密度遠心 IKGZ: 等連遠心 P■: 潅流指数 * 著しく有意な促進指標における偏差補正音の写しく翻訳文)提出書 (特許 法第184条の7第1項) 平成6年4月13日Average value + SEM After IPGZ IKGZ posterior insula volume (μm) 321±44. 2 315.5 ± 39.4 Survival rate (%) 99.2 ± 0.3 99.1 + 0 .. 4 Immunogenicity 100% * 24% ± 6.4% * (Irritation index after IPGZ = 10 0%) I PGZ: Isopycnal centrifugation IKGZ: isotonic centrifugation P■: Perfusion index * Transcript and translation of deviation correction sound in significantly significant promotion indicators) Submission form (patent (Article 184-7, Paragraph 1 of the Act) April 13, 1994
Claims (1)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4227066.9 | 1992-08-16 | ||
| DE4227066A DE4227066A1 (en) | 1992-08-16 | 1992-08-16 | Langerhans Islands in pure form |
| PCT/EP1993/002178 WO1994004169A1 (en) | 1992-08-16 | 1993-08-16 | Langerhans' islets in pure form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07500504A true JPH07500504A (en) | 1995-01-19 |
Family
ID=6465645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6505891A Withdrawn JPH07500504A (en) | 1992-08-16 | 1993-08-16 | Langerhans in its pure form |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0610473A1 (en) |
| JP (1) | JPH07500504A (en) |
| AU (1) | AU680828B2 (en) |
| CA (1) | CA2120724A1 (en) |
| DE (1) | DE4227066A1 (en) |
| WO (1) | WO1994004169A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011024575A (en) * | 2009-07-01 | 2011-02-10 | Takara Bio Inc | Method for separating cell |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0755258T3 (en) * | 1994-04-13 | 2002-05-13 | Res Corp Technologies Inc | Method of treating disease using Sertoli cells and allo-graft or xeno-graft |
| SG11201602232UA (en) | 2013-09-24 | 2016-04-28 | Giner Inc | System for gas treatment of a cell implant |
| AU2017361260B2 (en) | 2016-11-15 | 2023-06-08 | Giner, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
| CN110831656A (en) | 2017-05-04 | 2020-02-21 | 吉纳生命科学公司 | Robust implantable gas delivery devices and methods, systems, and devices including the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3468611A (en) * | 1966-05-10 | 1969-09-23 | Lawrence T Ward | Liquid applicator |
| JPS6345334U (en) * | 1986-09-12 | 1988-03-26 | ||
| JPH04119898A (en) * | 1990-09-11 | 1992-04-21 | Jiro Hori | Marker |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4868121A (en) * | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
-
1992
- 1992-08-16 DE DE4227066A patent/DE4227066A1/en not_active Withdrawn
-
1993
- 1993-08-16 AU AU47099/93A patent/AU680828B2/en not_active Ceased
- 1993-08-16 CA CA002120724A patent/CA2120724A1/en not_active Abandoned
- 1993-08-16 JP JP6505891A patent/JPH07500504A/en not_active Withdrawn
- 1993-08-16 EP EP93917795A patent/EP0610473A1/en not_active Withdrawn
- 1993-08-16 WO PCT/EP1993/002178 patent/WO1994004169A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3468611A (en) * | 1966-05-10 | 1969-09-23 | Lawrence T Ward | Liquid applicator |
| JPS6345334U (en) * | 1986-09-12 | 1988-03-26 | ||
| JPH04119898A (en) * | 1990-09-11 | 1992-04-21 | Jiro Hori | Marker |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011024575A (en) * | 2009-07-01 | 2011-02-10 | Takara Bio Inc | Method for separating cell |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4227066A1 (en) | 1994-02-17 |
| EP0610473A1 (en) | 1994-08-17 |
| AU4709993A (en) | 1994-03-15 |
| AU680828B2 (en) | 1997-08-14 |
| CA2120724A1 (en) | 1994-03-03 |
| WO1994004169A1 (en) | 1994-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008249204B2 (en) | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells | |
| US8057789B2 (en) | Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells | |
| JPH03501207A (en) | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor blood cells | |
| IL156303A (en) | Method of collecting placental stem cells from a post-partum human placenta | |
| JPH02504222A (en) | Methods for isolating subtype cell clusters from organs | |
| CN110959606A (en) | Immune effector cell cryopreservation solution and use thereof | |
| KR20100084620A (en) | Cell composition for tissue regeneration | |
| CN116904394A (en) | Preparation method and application of anti-inflammatory mesenchymal stem cell-derived exosome | |
| JPS60123422A (en) | How to regulate blood sugar in humans | |
| JPH07500504A (en) | Langerhans in its pure form | |
| ES2299417T3 (en) | METHOD FOR PRODUCING PREPARATIONS OF MATURE AND IMMATURE PANCREATIC ENDOCRINE CELLS, PREPARATION OF CELLS AND ITS USE FOR THE TREATMENT OF MELLITUS DIABETES. | |
| CN115317519B (en) | Use of adipose-derived mesenchymal stem cells in the preparation of drugs for treating feline fatty liver | |
| Ryan | Tissue Transplantation from Aborted Fetuses, Organ Transplantation from Anencephalic Infants and Keeping Brain-Dead Pregnant Women Alive Until Fetal Viability | |
| Khudri et al. | Exploring hematopoietic stem cell population in human milk and its benefits for infants: A scoping review | |
| EP1066833B1 (en) | Use of cryopreserved activated lymphocytes as a medicament | |
| Berney et al. | Islet Allotransplantation | |
| CN109125348A (en) | Umbilical cord mesenchymal stem cells combine application of the vitamin D in treatment diabetes medicament | |
| Touraine | In utero fetal liver cell transplantation in the treatment of immunodeficient or thalassemic human fetuses | |
| CN114807029A (en) | Method for separating and preparing CIK cells | |
| Khryshchanovich et al. | Clinical results of parathyroid cells allotransplantation | |
| CN119302294A (en) | Cell cryopreservation protection solution and cell cryopreservation method | |
| EP2301343A1 (en) | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells | |
| Moorhead | Therapeutic interactions in terminal renal failure | |
| Coffe et al. | Recent Changes in Patient Population: a Mission for Blood Banks | |
| Lake | Studies on the isolation and transplantation of mammalian pancreatic islets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080801 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090801 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090801 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100801 Year of fee payment: 13 |
|
| LAPS | Cancellation because of no payment of annual fees |